Global Rare Disease Treatment Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 103

Report ID: 4061

A rare disease is any disease that affects a small percentage of the population.
Most rare diseases are genetic and thus are present throughout the person's entire life, even if symptoms do not immediately appear.
In 2018, the global Rare Disease Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Rare Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Rare Disease Treatment development in United States, Europe and China.

The key players covered in this study
Novartis
Pfizer
F. Hoffmann-La Roche
Celgene
AbbVie
Johnson & Johnson
Shire
Alexion
Novo Nordisk
Sanofi
Bayer
Amgen
Allergan
Eisai
Bristol-Myers Squibb
Merck
Vertex Pharmaceuticals
Baxter
BioMarin
Teva Pharmaceutical Industries

Market segment by Type, the product can be split into
Originator Drugs
Generic Drugs

Market segment by Application, split into
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Rare Disease Treatment status, future forecast, growth opportunity, key market and key players.
To present the Rare Disease Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Rare Disease Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Rare Disease Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Originator Drugs
1.4.3 Generic Drugs
1.5 Market by Application
1.5.1 Global Rare Disease Treatment Market Share by Application (2014-2025)
1.5.2 Hospital Pharmacies
1.5.3 Specialty Pharmacies
1.5.4 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Rare Disease Treatment Market Size
2.2 Rare Disease Treatment Growth Trends by Regions
2.2.1 Rare Disease Treatment Market Size by Regions (2014-2025)
2.2.2 Rare Disease Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Rare Disease Treatment Market Size by Manufacturers
3.1.1 Global Rare Disease Treatment Revenue by Manufacturers (2014-2019)
3.1.2 Global Rare Disease Treatment Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Rare Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Rare Disease Treatment Key Players Head office and Area Served
3.3 Key Players Rare Disease Treatment Product/Solution/Service
3.4 Date of Enter into Rare Disease Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Rare Disease Treatment Market Size by Type (2014-2019)
4.2 Global Rare Disease Treatment Market Size by Application (2014-2019)

5 United States
5.1 United States Rare Disease Treatment Market Size (2014-2019)
5.2 Rare Disease Treatment Key Players in United States
5.3 United States Rare Disease Treatment Market Size by Type
5.4 United States Rare Disease Treatment Market Size by Application

6 Europe
6.1 Europe Rare Disease Treatment Market Size (2014-2019)
6.2 Rare Disease Treatment Key Players in Europe
6.3 Europe Rare Disease Treatment Market Size by Type
6.4 Europe Rare Disease Treatment Market Size by Application

7 China
7.1 China Rare Disease Treatment Market Size (2014-2019)
7.2 Rare Disease Treatment Key Players in China
7.3 China Rare Disease Treatment Market Size by Type
7.4 China Rare Disease Treatment Market Size by Application

8 Japan
8.1 Japan Rare Disease Treatment Market Size (2014-2019)
8.2 Rare Disease Treatment Key Players in Japan
8.3 Japan Rare Disease Treatment Market Size by Type
8.4 Japan Rare Disease Treatment Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Rare Disease Treatment Market Size (2014-2019)
9.2 Rare Disease Treatment Key Players in Southeast Asia
9.3 Southeast Asia Rare Disease Treatment Market Size by Type
9.4 Southeast Asia Rare Disease Treatment Market Size by Application

10 India
10.1 India Rare Disease Treatment Market Size (2014-2019)
10.2 Rare Disease Treatment Key Players in India
10.3 India Rare Disease Treatment Market Size by Type
10.4 India Rare Disease Treatment Market Size by Application

11 Central & South America
11.1 Central & South America Rare Disease Treatment Market Size (2014-2019)
11.2 Rare Disease Treatment Key Players in Central & South America
11.3 Central & South America Rare Disease Treatment Market Size by Type
11.4 Central & South America Rare Disease Treatment Market Size by Application

12 International Players Profiles
12.1 Novartis
12.1.1 Novartis Company Details
12.1.2 Company Description and Business Overview
12.1.3 Rare Disease Treatment Introduction
12.1.4 Novartis Revenue in Rare Disease Treatment Business (2014-2019)
12.1.5 Novartis Recent Development
12.2 Pfizer
12.2.1 Pfizer Company Details
12.2.2 Company Description and Business Overview
12.2.3 Rare Disease Treatment Introduction
12.2.4 Pfizer Revenue in Rare Disease Treatment Business (2014-2019)
12.2.5 Pfizer Recent Development
12.3 F. Hoffmann-La Roche
12.3.1 F. Hoffmann-La Roche Company Details
12.3.2 Company Description and Business Overview
12.3.3 Rare Disease Treatment Introduction
12.3.4 F. Hoffmann-La Roche Revenue in Rare Disease Treatment Business (2014-2019)
12.3.5 F. Hoffmann-La Roche Recent Development
12.4 Celgene
12.4.1 Celgene Company Details
12.4.2 Company Description and Business Overview
12.4.3 Rare Disease Treatment Introduction
12.4.4 Celgene Revenue in Rare Disease Treatment Business (2014-2019)
12.4.5 Celgene Recent Development
12.5 AbbVie
12.5.1 AbbVie Company Details
12.5.2 Company Description and Business Overview
12.5.3 Rare Disease Treatment Introduction
12.5.4 AbbVie Revenue in Rare Disease Treatment Business (2014-2019)
12.5.5 AbbVie Recent Development
12.6 Johnson & Johnson
12.6.1 Johnson & Johnson Company Details
12.6.2 Company Description and Business Overview
12.6.3 Rare Disease Treatment Introduction
12.6.4 Johnson & Johnson Revenue in Rare Disease Treatment Business (2014-2019)
12.6.5 Johnson & Johnson Recent Development
12.7 Shire
12.7.1 Shire Company Details
12.7.2 Company Description and Business Overview
12.7.3 Rare Disease Treatment Introduction
12.7.4 Shire Revenue in Rare Disease Treatment Business (2014-2019)
12.7.5 Shire Recent Development
12.8 Alexion
12.8.1 Alexion Company Details
12.8.2 Company Description and Business Overview
12.8.3 Rare Disease Treatment Introduction
12.8.4 Alexion Revenue in Rare Disease Treatment Business (2014-2019)
12.8.5 Alexion Recent Development
12.9 Novo Nordisk
12.9.1 Novo Nordisk Company Details
12.9.2 Company Description and Business Overview
12.9.3 Rare Disease Treatment Introduction
12.9.4 Novo Nordisk Revenue in Rare Disease Treatment Business (2014-2019)
12.9.5 Novo Nordisk Recent Development
12.10 Sanofi
12.10.1 Sanofi Company Details
12.10.2 Company Description and Business Overview
12.10.3 Rare Disease Treatment Introduction
12.10.4 Sanofi Revenue in Rare Disease Treatment Business (2014-2019)
12.10.5 Sanofi Recent Development
12.11 Bayer
12.12 Amgen
12.13 Allergan
12.14 Eisai
12.15 Bristol-Myers Squibb
12.16 Merck
12.17 Vertex Pharmaceuticals
12.18 Baxter
12.19 BioMarin
12.20 Teva Pharmaceutical Industries

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details